Immunoprevention and immunotherapy of mammary carcinoma

Pier Luigi Lollini, Giordano Nicoletti, Lorena Landuzzi, Carla De Giovanni, Patrizia Nanni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Cancer immunoprevention posits that the enhancement of immune defenses in healthy individuals could control tumor onset. Immunoprevention of viral tumors is already implemented at the population level for human hepatocellular and cervical carcinomas. Altogether, viral vaccines could prevent more than 10% of all human tumors. The big question is whether immunoprevention can be applied to nonviral tumors, including breast cancer. Promising results were obtained in preclinical models, in particular in HER-2/neu transgenic mice, which are prone to mammary carcinoma development, using vaccines against HER-2/neu oncoprotein p185. The life expectancy of vaccinated mice was more than doubled. Protective immune mechanisms elicited by effective vaccines were mainly based on helper T cell cytokines, in particular ?-interferon, and anti-p185 antibodies. The term "oncoantigens" was coined to define those antigenic molecules that, like HER-2, are indispensable for tumor growth, thus representing the best class of targets for cancer immunoprevention. The study of immunopreventive vaccines against subsequent phases of neoplastic progression showed a dramatic loss of efficacy against established mammary carcinomas, whereas the prevention of micrometastasis growth was successful. Preclinical results provide useful indications for the translation of cancer immunoprevention to humans, and useful hints for cancer immunotherapy.

Original languageEnglish
JournalBreast Journal
Volume16
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Immunotherapy
Breast Neoplasms
Neoplasms
Vaccines
Viral Vaccines
Neoplasm Micrometastasis
Oncogene Proteins
Growth
Helper-Inducer T-Lymphocytes
Life Expectancy
Interferons
Transgenic Mice
Anti-Idiotypic Antibodies
Hepatocellular Carcinoma
Cytokines
Population

Keywords

  • cancer vaccines
  • HER-2
  • immunoprevention
  • mammary carcinoma
  • oncoantigens

ASJC Scopus subject areas

  • Internal Medicine
  • Oncology
  • Surgery

Cite this

Immunoprevention and immunotherapy of mammary carcinoma. / Lollini, Pier Luigi; Nicoletti, Giordano; Landuzzi, Lorena; De Giovanni, Carla; Nanni, Patrizia.

In: Breast Journal, Vol. 16, No. SUPPL. 1, 09.2010.

Research output: Contribution to journalArticle

Lollini, Pier Luigi ; Nicoletti, Giordano ; Landuzzi, Lorena ; De Giovanni, Carla ; Nanni, Patrizia. / Immunoprevention and immunotherapy of mammary carcinoma. In: Breast Journal. 2010 ; Vol. 16, No. SUPPL. 1.
@article{25b3813c4c0348c2b9aa7a9290712738,
title = "Immunoprevention and immunotherapy of mammary carcinoma",
abstract = "Cancer immunoprevention posits that the enhancement of immune defenses in healthy individuals could control tumor onset. Immunoprevention of viral tumors is already implemented at the population level for human hepatocellular and cervical carcinomas. Altogether, viral vaccines could prevent more than 10{\%} of all human tumors. The big question is whether immunoprevention can be applied to nonviral tumors, including breast cancer. Promising results were obtained in preclinical models, in particular in HER-2/neu transgenic mice, which are prone to mammary carcinoma development, using vaccines against HER-2/neu oncoprotein p185. The life expectancy of vaccinated mice was more than doubled. Protective immune mechanisms elicited by effective vaccines were mainly based on helper T cell cytokines, in particular ?-interferon, and anti-p185 antibodies. The term {"}oncoantigens{"} was coined to define those antigenic molecules that, like HER-2, are indispensable for tumor growth, thus representing the best class of targets for cancer immunoprevention. The study of immunopreventive vaccines against subsequent phases of neoplastic progression showed a dramatic loss of efficacy against established mammary carcinomas, whereas the prevention of micrometastasis growth was successful. Preclinical results provide useful indications for the translation of cancer immunoprevention to humans, and useful hints for cancer immunotherapy.",
keywords = "cancer vaccines, HER-2, immunoprevention, mammary carcinoma, oncoantigens",
author = "Lollini, {Pier Luigi} and Giordano Nicoletti and Lorena Landuzzi and {De Giovanni}, Carla and Patrizia Nanni",
year = "2010",
month = "9",
doi = "10.1111/j.1524-4741.2010.01002.x",
language = "English",
volume = "16",
journal = "Breast Journal",
issn = "1075-122X",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Immunoprevention and immunotherapy of mammary carcinoma

AU - Lollini, Pier Luigi

AU - Nicoletti, Giordano

AU - Landuzzi, Lorena

AU - De Giovanni, Carla

AU - Nanni, Patrizia

PY - 2010/9

Y1 - 2010/9

N2 - Cancer immunoprevention posits that the enhancement of immune defenses in healthy individuals could control tumor onset. Immunoprevention of viral tumors is already implemented at the population level for human hepatocellular and cervical carcinomas. Altogether, viral vaccines could prevent more than 10% of all human tumors. The big question is whether immunoprevention can be applied to nonviral tumors, including breast cancer. Promising results were obtained in preclinical models, in particular in HER-2/neu transgenic mice, which are prone to mammary carcinoma development, using vaccines against HER-2/neu oncoprotein p185. The life expectancy of vaccinated mice was more than doubled. Protective immune mechanisms elicited by effective vaccines were mainly based on helper T cell cytokines, in particular ?-interferon, and anti-p185 antibodies. The term "oncoantigens" was coined to define those antigenic molecules that, like HER-2, are indispensable for tumor growth, thus representing the best class of targets for cancer immunoprevention. The study of immunopreventive vaccines against subsequent phases of neoplastic progression showed a dramatic loss of efficacy against established mammary carcinomas, whereas the prevention of micrometastasis growth was successful. Preclinical results provide useful indications for the translation of cancer immunoprevention to humans, and useful hints for cancer immunotherapy.

AB - Cancer immunoprevention posits that the enhancement of immune defenses in healthy individuals could control tumor onset. Immunoprevention of viral tumors is already implemented at the population level for human hepatocellular and cervical carcinomas. Altogether, viral vaccines could prevent more than 10% of all human tumors. The big question is whether immunoprevention can be applied to nonviral tumors, including breast cancer. Promising results were obtained in preclinical models, in particular in HER-2/neu transgenic mice, which are prone to mammary carcinoma development, using vaccines against HER-2/neu oncoprotein p185. The life expectancy of vaccinated mice was more than doubled. Protective immune mechanisms elicited by effective vaccines were mainly based on helper T cell cytokines, in particular ?-interferon, and anti-p185 antibodies. The term "oncoantigens" was coined to define those antigenic molecules that, like HER-2, are indispensable for tumor growth, thus representing the best class of targets for cancer immunoprevention. The study of immunopreventive vaccines against subsequent phases of neoplastic progression showed a dramatic loss of efficacy against established mammary carcinomas, whereas the prevention of micrometastasis growth was successful. Preclinical results provide useful indications for the translation of cancer immunoprevention to humans, and useful hints for cancer immunotherapy.

KW - cancer vaccines

KW - HER-2

KW - immunoprevention

KW - mammary carcinoma

KW - oncoantigens

UR - http://www.scopus.com/inward/record.url?scp=78649245853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649245853&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4741.2010.01002.x

DO - 10.1111/j.1524-4741.2010.01002.x

M3 - Article

C2 - 21050308

AN - SCOPUS:78649245853

VL - 16

JO - Breast Journal

JF - Breast Journal

SN - 1075-122X

IS - SUPPL. 1

ER -